contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


herantis-pharma-invitation-to-1h-2024-report-webinar-on-august-22-2024

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Herantis Pharma är ett bioteknikbolag i klinisk fas som utvecklar sjukdomsmodifierande terapier för Parkinsons sjukdom. Bolagets ledande produkt HER-096 är en liten syntetisk kemisk peptidomimetisk molekyl utvecklad baserat på CDNF-proteinets aktiva plats. HER-096 kombinerar verkningsmekanismen för CDNF med subkutan administrering. Herantis Pharma grundades 2008 och har sitt huvudkontor i Esbo, Finland.

Antti Vuolanto, VD för Herantis Pharma, berättar om bioteknikföretaget som en investeringsmöjlighet.                    Inderes              Herantis Pharma as an Investment | Life Science Night Dec. 2, 2024 -...    Time: 2024-12-03 13:50 Antti Vuolanto, CEO, talks about biotechnology company Herantis Pharma as an investment.

New series of articles! We are starting a series of articles focusing on the basics of investing in Life Science companies. This first part of the series describes the clinical phases of drug development that most drug development companies have to go through before they can apply for marketing authorization and commercialize a drug.                  Inderes              Clinical phases of drug development - Inderes    We are starting a series of articles focusing on the basics of investing in Life Science companies. This first part of the series describes the clinical phases of drug development that most drug development companies have to go through before they...

Pia intervjuade chefsanalytiker Antti Siltanen och de diskuterade självklart detta företag.  We have initiated coverage of Herantis Pharma, a drug development company focused on neurodegenerative diseases. In this interview analyst Antti Siltanen sheds light on what the company does, what its drug candidate HER-096 is all about, competing drug candidates and other pressing questions regarding the company.                   Inderes              Herantis Pharma: Disease-modifying drug for Parkinson’s - Inderes    Time: 2024-06-26 11:53 We have initiated coverage of Herantis Pharma, a drug development company focused on neurodegenerative diseases. In this interview analyst Antti Siltanen sheds light on what the company does, what its drug candidate HER-096 is...                             Content: 00:00 Intro  00:16 What does Herantis do?  00:52 How does HER-096 work?  01:20 Risks  03:19 Competing drug candidates  04:57 Capital adequacy and funding options  06:23 Probability of commercialization  07:12 When to expect profit generation?

Herantis Pharma är ett finländskt bioteknikföretag som specialiserar sig på läkemedelsforskning och utvecklar behandlingar för flera sjukdomar, såsom Parkinsons sjukdom, skleros och bröstcancer. Företaget har en bred produktportfölj i olika kliniska faser. Herantis Pharma bildades genom en sammanslagning av Hermo Pharma och Laurantis Pharma och har sitt huvudkontor i Esbo.  Många har säkert höga förväntningar på det här företaget. Visst finns det risker, men också stor potential. Jag behöver inte berätta mer om företaget eftersom en av Inderes’ bästa aktieanalytiker har gjort en ny utmärkt och lättläst analys av företaget, där du hittar all eller nästan all information du söker om företaget. Här är analysen gjord av analytikern @antti.siltanen: Herantis is a drug development company focused on neurodegenerative diseases. Herantis currently has one candidate in the clinical Phase I, HER-096, which the company develops as a disease-modifying drug for Parkinson’s disease. The risk level of the stock as an investment is very high, as the likelihood of successful drug development is still low due to the early development phase. As a counterbalance, the market for Parkinson’s disease is large and no disease-modifying drugs are available yet. Our DCF model suggests that the stock is attractively priced. Value creation can also materialize through a development and commercialization agreement or an acquisition. We initiate coverage with an Accumulate recommendation and a target price of EUR 2.2.                   Inderes              Herantis Pharma initiation of coverage: Early stage drug development requires...    Herantis is a drug development company focused on neurodegenerative diseases. Herantis currently has one candidate in the clinical Phase I, HER-096, which the company develops as a disease-modifying drug for Parkinson's disease.

Herantis Pharma

Press releaseHerantis Pharma Plc | Press Release | August 13, 2024 at 12:00:00 EESTHerantis Pharma: Invitation to 1H 2024 report webinar on August 22, 2024Herantis Pharma Plc (“Herantis”), a...

Press releaseHerantis Pharma Plc | Press Release | August 13, 2024 at 12:00:00 EESTHerantis Pharma: Invitation to 1H 2024 report webinar on August 22, 2024Herantis Pharma Plc (“Herantis”),&nbsp;a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease will webcast the 1H 2024 results,&nbsp;Thursday August 22 at 10:00 am EEST (9:00 CEST). The presentation will be held by CEO Antti Vuolanto and CFO Tone Kvåle, followed by a Q&amp;A session.Herantis will release 1H 2024 Report on August 22 at 8:00 am EEST (7:00 CEST). The report and presentation materials will be made available online at&nbsp;<a href="http://www.herantis.com/">www.herantis.com</a>.Please use the following link to register for this event: <a href="https://herantis.videosync.fi/2024-h1-results">https://herantis.videosync.fi/2024-h1-results</a>After registering, you will receive a confirmation email containing information about joining the webcast. Questions can be submitted throughout the webcast event.Following the webcast of the live call, a recording will be available on Herantis Pharma’s website:&nbsp;<a href="https://herantis.com/news-events/video-presentations/">https://herantis.com/news-events/video-presentations/</a>For more information, please contact: Tone Kvåle, CFO Tel: +47 915 19576 Email:&nbsp;<a href="mailto:ir@herantis.com">ir@herantis.com</a>Certified Advisor: UB Corporate Finance LtdTel: +358 9 25 380&nbsp;225Email: <a href="mailto:ubcf@unitedbankers.fi">ubcf@unitedbankers.fi</a>About Herantis Pharma PlcHerantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096, is an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. It combines the compelling mechanism of action of CDNF with the convenience of subcutaneous administration. The Phase 1a clinical trial demonstrated a good safety and tolerability profile, and efficient blood-brain barrier penetration of subcutaneously administered HER-096 in humans. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.Company website:&nbsp;<a href="http://www.herantis.com/">www.herantis.com</a>

Beställ vårt nyhetsbrev — inget användarkonto krävs!